Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

Abroad (travel likely)RecruitingPHASE1

Conditions

Irritable Bowel Syndrome · Gallstone Disease · GERD · Biliary Dyskinesia · Postcholecystectomy Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Federal Budgetary Institution of Science "North-West Public Health Research Center", Saint Petersburg, Russia
Contact: Study coordinator (Elena Shalukho) · Elena.Shalukho@yandex.ru · +7 (903) 099 57 86

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis

Irritable Bowel Syndrome with Diarrhea · Purine Metabolism Disorder

Abroad (travel likely)RecruitingEARLY_PHASE1

Nanjing, China · Nanjing, China

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

Irritable Bowel Syndrome · Constipation

Abroad (travel likely)RecruitingPHASE2

Mesa, United States · Anaheim, United States

Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome · Food Sensitivity

Abroad (travel likely)Recruiting

Gothenburg, Sweden

Anxiety and Depression in IBS: A Brain-Gut Axis Study

Irritable Bowel Syndrome (IBS) · Anxiety · Depression

Abroad (travel likely)Recruiting

Xi'an, China